Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several claims align with the provided DETROL label excerpts (indication and common adverse events like dry mouth/constipation), but many other claims (generic substitution/interchangeability, FDA generics design intentions, blurred vision/trouble urinating, QT/side-effect variability, and multiple administration-switch recommendations) are not supported by the supplied label text and cannot be verified.
Category Scores
Accurate Statements
Detrol is a brand name for tolterodine.
Provided label shows drug: DETROL (tolterodine tartrate) with active moiety tolterodine.
Tolterodine is used to treat overactive bladder symptoms such as urgency.
Indication: overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Tolterodine is used to treat overactive bladder symptoms such as frequency.
Indication: overactive bladder with symptoms ... urgency, and frequency.
Tolterodine is used to treat overactive bladder symptoms such as urge incontinence.
Indication: overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Common side effects include dry mouth.
Adverse reactions highlights: most common adverse events include dry mouth; dry mouth reported in 34.8%.
Common side effects include constipation.
Adverse reactions highlights list constipation among most common adverse events.
Unsupported Statements
Generic versions of Detrol are typically sold under the active ingredient name 'tolterodine.'
No provided label text addresses naming practices for generics.
Some generic tolterodine products are made as extended-release formulations.
Provided label excerpts for DETROL Tablets are immediate-release; no excerpt supports existence or frequency of extended-release generic products.
The exact generic tolterodine available depends on the country.
No provided label text addresses country-specific availability.
The exact generic tolterodine available depends on whether the Detrol prescription was written for regular vs extended-release.
Label excerpts provided do not discuss substitution/availability decisions based on prescription type.
FDA-approved generics are designed to have the same active ingredient as their brand counterparts.
No provided label text contains FDA generic design statements.
FDA-approved generics are designed to have comparable absorption as their brand counterparts.
No provided label text contains statements about FDA generic absorption design.
FDA-approved generics are used as substitutes for their brand counterparts.
No provided label text discusses substitution rules or interchangeability.
Interchangeability of generics can depend on formulation (for example, extended-release vs immediate-release).
No provided label text discusses generic interchangeability criteria by formulation.
Generic 'Detrol' products contain tolterodine.
No provided label text states composition of generics.
Tolterodine has a side-effect profile common to antimuscarinic drugs used for overactive bladder.
Label excerpt states expected side effects of antimuscarinic agents, but does not support a generalization phrased as 'common to antimuscarinic drugs used for overactive bladder.'
Common side effects include blurred vision.
Label excerpt mentions abnormal vision/accommodation abnormalities and xerophthalmia, but does not explicitly label 'blurred vision' as a common side effect.
Common side effects include trouble urinating.
Label excerpt lists urinary retention as expected side effect of antimuscarinic agents, but does not explicitly present 'trouble urinating' as a 'common side effect.'
The severity of tolterodine side effects can vary by dose.
No provided label excerpt states dose-dependent variation of adverse event severity.
The severity of tolterodine side effects can vary by individual tolerance.
No provided label excerpt states variation based on 'individual tolerance' for adverse event severity.
Switching from Detrol to a generic is usually possible if the generic matches both the active ingredient (tolterodine) and the formulation type.
Provided label excerpts do not discuss switching/substitution guidance or formulation matching for generics.
Switching is especially dependent on matching extended-release vs non–extended-release formulation.
No provided label excerpt provides interchangeability/switching guidance based on extended-release vs immediate-release.
If switching without matching the formulation, symptom control or side effects can change.
No provided label excerpt supports this statement about switching and changing outcomes.
It is recommended to ask whether the generic is the same tolterodine formulation as the current Detrol prescription.
No provided label excerpt contains pharmacy/clinical recommendation about asking substitution formulation.
It is recommended to confirm the strength and dosing schedule when switching.
No provided label excerpt supports this as a switching recommendation.
It is recommended to ask about substitution rules at the pharmacy.
No provided label excerpt contains guidance about pharmacy substitution rules.
It is recommended to ask whether the clinician wants a specific product.
No provided label excerpt contains guidance about requesting a specific product.
Contradictions
Important Omissions
No discussion of contraindications (urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, hypersensitivity) despite many safety-related claims being made.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While the label supports dry mouth and constipation as common adverse events and includes precautions for urinary retention and gastric retention, many generic substitution/switching recommendations are unsupported by the provided label excerpts and could lead to incorrect assumptions about interchangeability or risks when changing formulations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims about generic naming, FDA generic design/interchangeability, extended-release vs immediate-release substitution, and switching recommendations are not supported by the provided DETROL prescribing information excerpts.
Suggested Improvement
Restrict claims to what is explicitly supported by the DETROL label excerpts provided (e.g., indications; common adverse events like dry mouth and constipation; label-supported precautions such as risks of urinary/gastric retention). Remove or qualify generic substitution and switching guidance unless corresponding label text is provided.